Image

Multi-omics Analysis to Characterize the Invasive Evolution of Pulmonary Subsolid Nodules

Multi-omics Analysis to Characterize the Invasive Evolution of Pulmonary Subsolid Nodules

Not Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Current clinical follow-up frequency and treatment timing for pulmonary subsolid nodules (SSNs) rely mostly on whether the nodules grow, which may not accurately reflect the pathological status, and may lead to unnecessary follow-ups. This study aims to use multi-omics techniques to dynamically observe the growth and invasiveness evolution process of SSNs and uncover its invasiveness mechanism. Radiological characteristics of SSNs in different invasiveness stages were also analyzed and summarized by analyzing preoperative CT. This can overcome the bottleneck of invasiveness assessment in the growth process of SSN and provide scientific evidence for the scientific management and clinical treatment timing choice of SSN patients, thus facilitating the rational allocation of medical resources and prolonging the expected survival of national health.

Description

This prospective observational cohort study aims to recruit 120 patients with subsolid nodules (SSNs) and 100 healthy volunteers. Enroll 120 patients with SSNs planned for surgery and 100 healthy volunteers. Sequence blood and tissue samples from patients and compare the relevance of biomarkers between the two. Use blood from healthy volunteers as blank controls. Additionally, analyzes radiological characteristics of SSNs at different invasive stages using preoperative CT.

Eligibility

Inclusion Criteria:

Patients with SSNs

  1. Newly diagnosed patients with persistent SSNs confirmed by thin-section chest CT examination
  2. Patient areilling to undergo surgery
  3. Voluntarily sign a written informed consent form

Healthy Volunteers

  1. Healthy volunteers aged 18-50 years, regardless of gender.
  2. No lung nodules detected on chest thin-section CT.
  3. No history of cancer.
  4. Voluntary sign a written informed consent form.

Exclusion Criteria:

Patients with SSNs

  1. Surgical contraindications
  2. Inability to cooperate with CT/MR examination to obtain high-quality images
  3. History of malignant tumors
  4. Previous targeted, immune, or ablation therapy
  5. Postoperative pathology of non-lung adenocarcinoma disease spectrum
  6. Other situations deemed unsuitable for participation in this study by the researchers

Healthy Volunteers

  1. Drug abuse
  2. HIV infection or AIDS
  3. History of syphilis, gonorrhea, or other infectious diseases
  4. Hepatitis B or C virus carrier

Study details
    Adenocarcinoma of Lung

NCT06215885

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

30 January 2026

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.